Roxanne C. Jewell - Concepedia

Author

Roxanne C. Jewell

GlaxoSmithKline (United States)

Also Known As

Bertrand Coiffier, R C Jewell, R. C. Jewell, R.C. Jewell, Roxanne C Jewell, Roxanne C. Jewell, Roxanne Jewell

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)Research Triangle Park Foundation The University of Texas MD Anderson Cancer Center Genmab (Denmark)GlaxoSmithKline (United Kingdom)

About

Roxanne C. Jewell is an author at GlaxoSmithKline (United States) specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	1.1K
2	Health Sciences	3	3	118
3	Natural Sciences	2	2	45
4	Biochemistry	2	2	45
5	Engineering	1	1	10

Roxanne C. Jewell

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study Sagar Lonial, Hans C. Lee, Ashraf Badros, The Lancet Oncology Hematological MalignancyMedicinePathologyBelantamab MafodotinCancer Treatment	2019	772
Increased Oral Bioavailability of Topotecan in Combination With the Breast Cancer Resistance Protein and P-Glycoprotein Inhibitor GF120918 C.M.F. Kruijtzer, Jos H. Beijnen, Hilde Rosing, Journal of Clinical Oncology	2002	456
A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients I. E. L. M. Kuppens, Els O. Witteveen, Roxanne C. Jewell, Clinical Cancer Research	2007	174
Clinical and Biological Effects of Recombinant Human Interleukin-18 Administered by Intravenous Infusion to Patients with Advanced Cancer Michael J. Robertson, James W. Mier, Theodore F. Logan, Clinical Cancer Research	2006	167
Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients Mirte M. Malingré, Jos H. Beijnen, Hilde Rosing, British Journal of Cancer	2001	150
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study Myron S. Czuczman, Luis Fayad, Vincent Delwail, Blood	2012	125
A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors A. S. T. Planting, Pieter Sonneveld, Ate van der Gaast, Cancer Chemotherapy and Pharmacology OncologyMedicineAdvanced Solid TumorsMdr Converter Gf120918Anti-cancer Agent	2004	106
Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein Alex Sparreboom, André Planting, Roxanne C. Jewell, Anti-Cancer Drugs	1999	95
Pharmacokinetics of RheothRx Injection in Healthy Male Volunteers Roxanne C. Jewell, S P Khor, David F. Kisor, Journal of Pharmaceutical Sciences	1997	64
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma Matthew J. Matasar, Myron S. Czuczman, Maria Alma Rodriguez, Blood	2013	64

Page 1